Udruženost ekspresije IL-32 sa invazijom limfnih sudova u intestinalnom tipu karcinoma želuca
Sažetak
Uvod/Cilj. Karcinom želuca (KŽ) četvrti je najčešći maligni tumor širom sveta, često dijagnostikovan u naprednim stadijumima sa lošom prognozom. Cilj studije bio je da se utvrdi ekspresija IL-32, pro-inflamatornih i angiogenih medijatora u tumoru, peritumoru i zdravom tkivu kod bolesnika sa intestinalnim tipom KŽ, kao i povezanost sa težinom bolesti. Metode. U studiji su analizirani uzorci tkiva intestinalnog tipa tumora od 60 bolesnika sa KŽ. Ekspresija interleukina (IL)-32, vaskularnog endotelnog faktora rasta (engl. vascular endothelial growth factor – VEGF), IL-17 i CD31 merena je imunohistohemijskom metodom. Rezultati. Ekspresija IL-32, VEGF-a i IL-17, kao i mikrovaskularna gustina (engl. microvascular density – MVD) bili su smanjeni u peri-tumorskom tkivu u poređenju sa tumorskim tkivom. Intenzivnija ekspresija IL-32 i VEGF-a i pojačana MVD bili su registrovani kod bolesnika sa težim (TNM stadijumi III i IV) i progresivnijim karcinomom želuca (prisutna invazija limfnih sudova). Zaključak. Veća ekspresija IL-32, VEGF-a i intenzivnija MVD u tumorskom tkivu bolesnika sa KŽ i prisutnom invazijom limfnih sudova može se smatrati znakom progresije maligne bolesti. Ovaj rezultat ukazuje na protumorogenu i proangiogenu ulogu IL-32 u biologiji intestinalnog tipa KŽ.
Reference
Ang TL, Fock KM. Clinical epidemiology of gastric cancer. Singapore Med J 2014; 55(12): 621–8.
Lauren P. The two histological main types of gastric carcino-ma: Diffuse and so-called intestinal-type carcinoma. An at-tempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31–49.
Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer 2010; 102(2): 237–42.
Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007; 133(2): 659–72.
Correa P. Gastric cancer: overview. Gastroenterol Clin North Am 2013; 42(2): 211–7.
Bondar’ VG, Saliev IA, Ostapenko GV, Bondar’ GV. Late diag-nosis, complications and treatment of gastric cancer. Klin Khir 2006; (3): 8–13. (Bulgarian)
Joosten LA, Heinhuis B, Netea MG, Dinarello CA. Novel in-sights into the biology of interleukin-32. Cell Mol Life Sci 2013; 70(20): 3883–92.
Kim S. Interleukin-32 in inflammatory autoimmune diseases. Immune Netw 2014; 14(3): 123–7.
Choi J Da, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, et al. Identification of the most active interleukin-32 isoform. Immunology 2009; 126(4): 535–42.
Kobayashi H, Lin PC. Molecular characterization of IL-32 in human endothelial cells. Cytokine 2009; 46(3): 351–8.
Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Inter-leukin 32, inflammation and cancer. Pharmacol Ther 2017; 174: 127–37.
Hu LJ, Li L, Fitzpatrick JE, Francis SO, Fujita M, Takashi MK, et al. The Proinflammatory Cytokine Interleukin-32 is ex-pressed in Keratinocytes and Dendritic Cells Obtained from Patients with Chronic Plaque Psoriasis (CPPs). J Immunol 2007; 178(Meeting Abstracts): S165.
Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A 2006; 103(9): 3298–303.
Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, et al. IL-32 promotes angiogenesis. J Immunol 2014; 192(2): 589–602.
Yang Y, Wang Z, Zhou Y, Wang X, Xiang J, Chen Z. Dysregula-tion of over-expressed IL-32 in colorectal cancer induces me-tastasis. World J Surg Oncol 2015; 13: 146.
Smith AJ, Toledo CM, Wietgrefe SW, Duan L, Schacker TW, Reil-ly CS, et al. The immunosuppressive role of IL-32 in lymphat-ic tissue during HIV-1 infection. J Immunol 2011; 186(11): 6576–84.
Yun J, Park MH, Son DJ, Nam KT, Moon DB, Ju JH, et al. IL-32 gamma reduces lung tumor development through upregula-tion of TIMP-3 overexpression and hypomethylation. Cell Death Dis 2018; 9(3): 306.
Yousif NG, Al-Amran FG, Hadi N, Lee J, Adrienne J. Expres-sion of IL-32 modulates NF-kappaB and p38 MAP kinase pathways in human esophageal cancer. Cytokine 2013; 61(1): 223–7.
Raica M, Mogoantă L, Cîmpean AM, Alexa A, Ioanovici S, Mărgăritescu C, et al. Immunohistochemical expression of vas-cular endothelial growth factor (VEGF) in intestinal type gas-tric carcinoma. Rom J Morphol Embryol 2008; 49(1): 37–42.
Lastraioli E, Boni L, Romoli MR, Crescioli S, Taddei A, Beghelli S, et al. VEGF-A clinical significance in gastric cancers: Im-munohistochemical analysis of a wide Italian cohort. Eur J Surg Oncol 2014; 40(10): 1291–8.
Iida T, Iwahashi M, Katsuda M, Ishida K, Nakamori M, Nakamu-ra M, et al. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progres-sion in human gastric cancer. Oncol Rep 2011; 25(5): 1271–7.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLO-BOCAN 2008. Int J Cancer 2010; 127(12): 2893–917.
Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132(5): 1133–45.
Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014; 23(5): 700–13.
Ma J, Shen H, Kapesa L, Zeng S. Lauren classification and indi-vidualized chemotherapy in gastric cancer. Oncol Lett 2016; 11(5): 2959–64.
Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol 2012; 3(3): 251–61.
Zhou Y, Zhu Y. Important Role of the IL-32 Inflammatory Network in the Host Response against Viral Infection. Viruses 2015; 7(6): 3116–29.
Kim KH, Shim JH, Seo EH, Cho MC, Kang JW, Kim SH, et al. Interleukin-32 monoclonal antibodies for Immunohistochem-istry, Western blotting, and ELISA. J Immunol Methods 2008; 333(1–2): 38–50.
Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ, et al. Detec-tion of expressed IL-32 in human stomach cancer using ELI-SA and immunostaining. J Microbiol Biotechnol 2008; 18(9): 1606–12.
Wang YM, Li ZX, Tang FB, Zhang Y, Zhou T, Zhang L, et al. Association of genetic polymorphisms of interleukins with gas-tric cancer and precancerous gastric lesions in a high-risk Chi-nese population. Tumor Biol 2016; 37(2): 2233–42.
Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng WL, Tseng YH, et al. Interleukin-32 increases human gastric cancer cell inva-sion associated with tumor progression and metastasis. Clin Cancer Res 2014; 20(9): 2276–88.
Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, et al. Cellular source and amount of vascular endothe-lial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res 2009; 69(10): 4527–36.
Lertkiatmongkol P, Liao D, Mei H, Hu Y, Newman PJ. Endothe-lial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr Opin Hematol 2016; 23(3): 253–9.
Privratsky JR, Newman PJ. PECAM-1: regulator of endothelial junctional integrity. Cell Tissue Res 2014; 355(3): 607–19.
Zhao HC, Qin R, Chen XX, Sheng X, Wu JF, Wang DB, et al. Microvessel density is a prognostic marker of human gastric cancer. World J Gastroenterol 2006; 12(47): 7598–603.
Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adeno-carcinoma. Clin Cancer Res 2000; 6(6): 2431–9.
Bo W, Yang T, Huan T, Shi-Lei W, Shi-Hang T, Hui H, et al. Correlations between VEGF-A expression and prognosis in patients with gastric adenocarcinoma. Int J Clin Exp Pathol 2017; 10(8): 8461–9
Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, et al. Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. Int J Mol Sci 2016; 17(9): pii: E1433.
Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival af-ter curative resection of hepatocellular carcinoma. J Clin On-col 2008; 26(16): 2707–16.
Tzoutzos K, Batistatou A, Kitsos G, Liasko R, Stefanou D. Study of microvascular density and expression of vascular endotheli-al growth factor and its receptors in cancerous and precancer-ous lesions of the eyelids. Anticancer Res 2014; 34(9): 4977–83.
Zhuang PY, Shen J, Zhu XD, Lu L, Wang L, Tang ZY, et al. Prognostic Roles of Cross-Talk between Peritumoral Hepato-cytes and Stromal Cells in Hepatocellular Carcinoma Involv-ing Peritumoral VEGF-C, VEGFR-1 and VEGFR-3. Sarkar D, editor. PLoS One 2013; 8(5): e64598.
Asukai K, Kawamoto K, Eguchi H, Konno M, Nishida N, Koseki J, et al. Prognostic Impact of Peritumoral IL-17-Positive Cells and IL-17 Axis in Patients with Intrahepatic Cholangiocarci-noma. Ann Surg Oncol 2015; 22 Suppl 3: S1524–31.